NJ-OPENGEAR
7.6.2022 14:02:36 CEST | Business Wire | Press release
Opengear , a Digi International company (NASDAQ, DGII, www.digi.com/ ) and leading network resilience solutions provider, announced today that it is launching its new family of console managers, the CM8100. As the latest addition to its award-winning Smart OOBTM Console Server family, the CM8100 delivers a comprehensive solution, adding NetOps capabilities to existing Smart OOB features that simplify connectivity to IT equipment. Moreover, it provides resilient and secure remote access to infrastructure devices while enhancing security and automation for better smart out-of-band management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005005/en/
“IT infrastructure needs to be resilient and easy to manage without relying on the network to manage the network,” says Gary Marks, President of Opengear. “Whether IT teams need to bring up new devices, manage existing ones or remediate outages, they must have resilient access to the network from anywhere. Regardless of the state of the production network, Opengear’s CM8100 provides engineers with the remote and reliable connectivity they need to be successful. It is yet another milestone in our long line of solutions designed to help engineers overcome today’s challenges such as travel requirements, security restrictions, and a lack of connectivity.”
CM8100 highlights:
- Hosts up to 48 managed serial connected devices
- Hardware-based TPM 2.0 security module providing data encryption and secure boot
- Open architecture REST API based firmware supporting automation tools, Docker, and Python scripting
- Four times faster than the previous generation while maintaining power-efficient and passively cooled operation up to 50C
- Dual AC power supplies with independent monitoring and alerting
The Opengear platform and CM8100 enhance console access with modern automation capabilities. The CM8100 also helps IT personnel remotely provision, manage and remediate devices. Likewise, it enables remote access to even the most sprawling and complex infrastructure, such as switches, routers, PDUs, firewalls, and other critical data center equipment. Additionally, CM8100 appliances establish secure VPN tunnels which connect IT, staff, to remote devices. This provides local access to Ethernet and RS-232 console ports via standard UTP patch cables. The resilient connection of the CM8100 is available to either IT staff or applications to configure managed devices.
“Nearly every enterprise is familiar with the ‘3 a.m.’ call about a down server or a network device but driving or even flying to a data center or remote site can be time-consuming and expensive,” adds Marks. “More than half of IT outages cost over $100,000 , so network issues must get fixed quickly. However, if engineers can’t access the network remotely and lack visibility, they will arrive at the site without the right tools or replacement devices to be successful in one trip. With the Opengear platform, IT personnel have the visibility to ascertain the problem from afar and also the access to remediate the outage remotely, saving considerable time and resources.”
For more information about the CM8100, visit https://opengear.com/products/cm8100-console-server/ .
To learn more about Opengear, visit: www.opengear.com .
About Opengear
Opengear, a Digi International company, delivers secure, resilient access and automation to support critical IT infrastructure, even when the network is down. Provisioning, orchestration, and remote management of network devices through innovative software and appliances enable technical staff to reliably and efficiently manage data centers and remote network locations. Opengear solutions are trusted by global organizations across financial, digital communications, retail and manufacturing industries. The company is headquartered in New Jersey, with R&D centers in Silicon Valley and Brisbane, Australia. Opengear was acquired by Digi International in 2019, bringing together two organizations with a deep commitment to providing the best products, software and services that meet the demands of mission-critical networks. For more information, please visit www.opengear.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005005/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
